Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Other Operating Expenses (2022 - 2024)

Taysha Gene Therapies (TSHA) has disclosed Other Operating Expenses for 3 consecutive years, with $4.8 million as the latest value for Q3 2024.

  • Quarterly Other Operating Expenses rose 685.39% to $4.8 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $4.8 million through Jun 2025, down 94.08% year-over-year, with the annual reading at $4.8 million for FY2024, 94.08% down from the prior year.
  • Other Operating Expenses hit $4.8 million in Q3 2024 for Taysha Gene Therapies, down from $81.2 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $81.2 million in Q4 2023 to a low of $616000.0 in Q3 2023.
  • Historically, Other Operating Expenses has averaged $32.0 million across 3 years, with a median of $36.4 million in 2022.
  • Biggest five-year swings in Other Operating Expenses: skyrocketed 122.88% in 2023 and later soared 685.39% in 2024.
  • Year by year, Other Operating Expenses stood at $36.4 million in 2022, then soared by 122.88% to $81.2 million in 2023, then crashed by 94.04% to $4.8 million in 2024.
  • Business Quant data shows Other Operating Expenses for TSHA at $4.8 million in Q3 2024, $81.2 million in Q4 2023, and $616000.0 in Q3 2023.